Aclaris Therapeutics (ACRS) Net Cash Flow (2014 - 2026)

Aclaris Therapeutics' Net Cash Flow history runs 13 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 50.34% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at -$1.7 million (up 69.06% YoY), while the FY2025 annual figure was -$4.6 million, up 69.89% from the prior year.
• Net Cash Flow was $8.7 million for Q1 2026 at Aclaris Therapeutics, up from -$5.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $31.9 million in Q2 2022 to a low of -$40.3 million in Q2 2023.
• Historically, Net Cash Flow has averaged -$1.5 million across 5 years, with a median of -$555000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow sank 2854.3% in 2024, then jumped 243.35% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$16.4 million in 2022, then soared by 105.12% to $838000.0 in 2023, then tumbled by 2854.3% to -$23.1 million in 2024, then jumped by 77.05% to -$5.3 million in 2025, then surged by 264.27% to $8.7 million in 2026.
• The last three Net Cash Flow figures came in at $8.7 million (Q1 2026), -$5.3 million (Q4 2025), and -$146000.0 (Q3 2025), per Business Quant data.